Tegaserod maleate (Zelnorm) is the first selective partial 5-HT4 agonist approved by FDA for the short-term treatment of irritable bowel syndrome (IBS) in women whose primary bowel symptom is constipation. To help you prepare for P & T Committee review, this article presents tegaserod?s chemistry and pharmacology, pharmacokinetics, clinical trial results, adverse effects profile, dosing information, cost, and the author?s opinion on its place in therapy.

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Tegaserod: A 5 HT4 agonist for women with constipation-predominant irritable bowel syndrome (PDF)

Newsletter